TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Bifocal and Prismatic Bifocal Spectacles for Myopia Control in Children
Brief Summary: 1. To determine if the effect of near-addition lenses (bifocals) is more prominent for children with high myopia progression.
2. To study how different subject characteristics such as age, gender, baseline degree of myopia, baseline near phoria and baseline lag of accommodation affect the efficacy of bifocal lens wear in myopic children.
3. To investigate the effect of incorporating near base-in prisms along with the near-addition lenses (prismatic bifocals) on myopia progression in myopic children.


Options:
A: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses
B: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
C: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals
D: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Bifocal and Prismatic Bifocal Spectacles for Myopia Control in Children
Brief Summary: 1. To determine if the effect of near-addition lenses (bifocals) is more prominent for children with high myopia progression.
2. To study how different subject characteristics such as age, gender, baseline degree of myopia, baseline near phoria and baseline lag of accommodation affect the efficacy of bifocal lens wear in myopic children.
3. To investigate the effect of incorporating near base-in prisms along with the near-addition lenses (prismatic bifocals) on myopia progression in myopic children.


Options:
A: Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle
B: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
C: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals
D: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Bifocal and Prismatic Bifocal Spectacles for Myopia Control in Children
Brief Summary: 1. To determine if the effect of near-addition lenses (bifocals) is more prominent for children with high myopia progression.
2. To study how different subject characteristics such as age, gender, baseline degree of myopia, baseline near phoria and baseline lag of accommodation affect the efficacy of bifocal lens wear in myopic children.
3. To investigate the effect of incorporating near base-in prisms along with the near-addition lenses (prismatic bifocals) on myopia progression in myopic children.


Options:
A: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL
B: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals
C: Intervention Type: DRUG; Name: 7-methylxanthine; Assigned to Arm(s): N/A
D: Arm Label: single vision soft contact lens; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Defocus Incorporated Soft Contact (DISC) lens; Type: EXPERIMENTAL; Interventions: Device: Defocus Incorporated Soft Contact (DISC) lens | Intervention Type: DEVICE; Name: Defocus Incorporated Soft Contact (DISC) lens; Assigned to Arm(s): Defocus Incorporated Soft Contact (DISC) lens

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Oral N-Acetyl Cysteine on Pregnancy Outcome After Cervical Cerclage: a Randomized Controlled Trial
Brief Summary: The aim of the study is to evaluate the effect of N-acetyl cysteine (NAC) on pregnancy outcome in women undergoing cervical cerclage for cervical insufficiency.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetyl Cysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-Acetyl Cysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Vaginal progesterone only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cervical cerclage plus vaginal progesterone; Type: EXPERIMENTAL; Interventions: Procedure: Cerclage | Intervention Type: PROCEDURE; Name: Cerclage; Assigned to Arm(s): Cervical cerclage plus vaginal progesterone
C: Arm Label: Vaginal progesterone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Arm Label: No progesterone group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Vaginal progesterone group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endoscopically Proven GERD
Brief Summary: The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).


Options:
A: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
B: Arm Label: Rabeprazole 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Arm Label: Rabeprazole 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 0.5 mg/kg | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 1.0 mg/kg
C: Intervention Type: DRUG; Name: pantoprazole for approximately 9 weeks.; Assigned to Arm(s): N/A
D: Arm Label: Low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Arm Label: High dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid suspension; Assigned to Arm(s): High dose, Low dose

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endoscopically Proven GERD
Brief Summary: The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).


Options:
A: Arm Label: Rabeprazole 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Arm Label: Rabeprazole 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 0.5 mg/kg | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 1.0 mg/kg
B: Arm Label: Rabeprazole sodium 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rabeprazole sodium 5 mg | Arm Label: Rabeprazole sodium 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Rabeprazole sodium 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rabeprazole sodium 5 mg; Assigned to Arm(s): Rabeprazole sodium 5 mg | Intervention Type: DRUG; Name: Rabeprazole sodium 10 mg; Assigned to Arm(s): Rabeprazole sodium 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dexlansoprazole MR 30 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 30 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD
D: Intervention Type: DRUG; Name: Esomeprazole (Nexium); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of a Forecasting System for Predicting Exacerbations of COPD: Effect on Symptoms and Hospitalisation and Relevance of Viral Infections
Brief Summary: People with Chronic Obstructive Pulmonary Disease (COPD) often have periods during the year when their symptoms become worse. These are often due to an infection and are called "exacerbations" by doctors. Exacerbations are more common in the winter and also seem to be related to particular types of weather. As well as forecasting the weather the UK Met Office has developed a system to try to predict when exacerbations are likely to occur. The main purpose of this research study is to find out whether the Met Office forecasting service can predict when exacerbations are more likely to occur and whether the advice given during the predicted higher risk periods leads to fewer patients having an exacerbation or if it reduces the impact of the exacerbation. The study will also assess if there is a link between viral or bacterial infection and breathing problems that occur during the study period. The study will also collect information about possible causes of the breathing problems and what happens to the person afterwards. The results of this study will help us learn more about breathing problems which may lead to new research studies that would aim to improve the care of people with COPD.


Options:
A: Arm Label: Home Monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Monitoring | Arm Label: In-Office Conventional Follow-up; Type: OTHER; Interventions: Other: In-Office Conventional Follow-up | Intervention Type: OTHER; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring | Intervention Type: OTHER; Name: In-Office Conventional Follow-up; Assigned to Arm(s): In-Office Conventional Follow-up
B: Arm Label: Home blood pressure telemonitoring; Type: N/A; Interventions: N/A | Arm Label: Conventional blood pressure measurement; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Directed Weight Loss Program | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Call-Center Directed (CCD) Weight Loss Program | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Directed (IPD) Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Call-Center Directed (CCD) Weight Loss Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: In-Person Directed (IPD) Weight Loss Program; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Self-Directed Weight Loss Program; Assigned to Arm(s): 1
D: Arm Label: Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice, Behavioral: Poor weather forecast warning | Arm Label: No Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD self care advice; Assigned to Arm(s): Forecast, No Forecast | Intervention Type: BEHAVIORAL; Name: Poor weather forecast warning; Assigned to Arm(s): Forecast

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-week, National, Single-centre, Open-labelled, Randomised, Parallel-group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes
Brief Summary: This is a study designed to compare the effects of 2 long-acting insulins, detemir and insulatard, on energy expenditure,weight, fat composition, gut hormone profiles, glycaemic control and fat and muscle gene expression over a 6 month period.


Options:
A: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901) [Lantus], Drug: Glimepiride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: human insulin [NPH] | Intervention Type: DRUG; Name: Insulin Glargine (HOE901) [Lantus]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: human insulin [NPH]; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: NPH human insulin; Assigned to Arm(s): N/A
D: Arm Label: 1. Insulatard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulatard | Arm Label: 2. Detemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Detemir | Intervention Type: DRUG; Name: Insulatard; Assigned to Arm(s): 1. Insulatard | Intervention Type: DRUG; Name: Detemir; Assigned to Arm(s): 2. Detemir

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Brief Intervention Opportunistic Targeting Parents Who Smoke to Reduce Exposure to Secondhand Smoke in Babies: STUDY BIBE
Brief Summary: Main objective: to determine the effectiveness of a brief opportunist educational performance directed to the parents who smoke -- inside the context of programmed visits of paediatrics in primary care -- to reduce the exposure of the babies to secondhand smoke (SHS)

Secondary objectives:

1. Smoking reduction / quitting of the mother and/or the father
2. To determine the relationship between the level exposure to SHS and main related variables


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention based in clinical practice guide | Intervention Type: BEHAVIORAL; Name: Brief intervention based in clinical practice guide; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: School-based Care; Type: EXPERIMENTAL; Interventions: Behavioral: School-based Care | Intervention Type: BEHAVIORAL; Name: School-based Care; Assigned to Arm(s): School-based Care
C: Arm Label: Clinic Quality Improvement + Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic Quality Improvement + Behavioral Counseling | Arm Label: Clinic Quality Improvement + Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic Quality Improvement + Attention Control | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Behavioral Counseling; Assigned to Arm(s): Clinic Quality Improvement + Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Attention Control; Assigned to Arm(s): Clinic Quality Improvement + Attention Control
D: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing Intervention for ETS Reduction | Arm Label: Education Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Program for ETS Reduction | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing Intervention for ETS Reduction; Assigned to Arm(s): Behavioral | Intervention Type: BEHAVIORAL; Name: Educational Program for ETS Reduction; Assigned to Arm(s): Education Only

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of an Extended Period of Varenicline Use Prior to Quitting Smoking on Post-quitting Urges to Smoke
Brief Summary: Varenicline (Champix) is a relatively new medicine that is effective in helping people to quit smoking. It is normally started 1-week before stopping smoking and used for up to 12-24 weeks. We are trying to find out if using varenicline for an extended time (4-weeks) before stopping smoking is better than the standard 1-week of use prior to stopping.

The study will recruit 100 smokers who want to stop. They will be randomly allocated to receive varenicline(4-weeks) or placebo (3-weeks followed by 1-week of active treatment as indicated by standard prescribing practice), followed by a 12-week open label treatment period where all participants will receive varenicline.


Options:
A: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of an Extended Period of Varenicline Use Prior to Quitting Smoking on Post-quitting Urges to Smoke
Brief Summary: Varenicline (Champix) is a relatively new medicine that is effective in helping people to quit smoking. It is normally started 1-week before stopping smoking and used for up to 12-24 weeks. We are trying to find out if using varenicline for an extended time (4-weeks) before stopping smoking is better than the standard 1-week of use prior to stopping.

The study will recruit 100 smokers who want to stop. They will be randomly allocated to receive varenicline(4-weeks) or placebo (3-weeks followed by 1-week of active treatment as indicated by standard prescribing practice), followed by a 12-week open label treatment period where all participants will receive varenicline.


Options:
A: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
C: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette | Arm Label: Assessments only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: E-cigarette; Assigned to Arm(s): E-Cigarette
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D